Home > Oncology > ELCC 2019 > Implementation of Personalised Lung Cancer Care in Clinical Routine > How can societies help to implement personalised treatment?

How can societies help to implement personalised treatment?

Presented By
Prof. Rolf Stahel, Prof. Giorgio Scagliotti
ELCC 2019
There were two lectures about the role of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) to help implement personalised treatment in clinical practice. ESMO provides tools that help in decision-making. In the recently updated ESMO guidelines, there are recommendations about which molecular aberrations could be present and how they should be tested. For the diagnosis of stage 4 lung cancer, the following molecular tests are recommended: ALK, BRAF, EGFR, and ROS1. Based on the aberrations present, a certain targeted therapy or several treatment options can be recommended [1]. “ESMO is not only intended for Europe and for medical oncologists, but ESMO expands to all professions”, Prof. Rolf Stahel (University Hospital of Zurich, Switzerland) said. Recently, the Asian colleagues adapted the ESMO guidelines and published an Asian version [2]. In Asia, ph...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on